CXCR3 and myeloid sarcoma: CD20+ T cells have a higher surface expression of CXCR3 than CD20- T cells (21), and given the higher level of both CD20+ T cells to be attracted and chemoattractant in patients with MS, a higher frequency in the CSF would be expected.